No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 5 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:52:33.145Z. Latest historical point 2024-09-30. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T17:52:33.145Z. Latest historical point 2024-09-30.
The latest delayed quote for NewGenIvf Group Limited (NIVF) stock was $0.10 as of Oct 6, 2026, 1:50 PM EDT, down 9.73% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -100.0% · 3-year avg -99.7%/yr
Operating out of its headquarters in Bangkok, Thailand, NewGenIvf Group Limited specializes in delivering assisted reproductive services. The firm is committed to fulfilling the desire for family through a variety of fertility treatments.
Medical - Care Facilities · Bangkok, BM
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Mar 3, 2027
148 days away
EPS Estimate
24.48
Revenue Est.
$45.10M
Last Quarter Results
EPS
$18.18
vs Estimate
$18.18
Revenue
$20.10M
vs Estimate
$20.10M
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NIVF | $6,273 | $0.10 | -9.73% | -99.99% | N/A | N/A | N/A |
| 2MNDR | $30,755 | $1.25 | -2.39% | -99.03% | N/A | N/A | vs NIVF |
| 3AKAN | $61,172 | $1.89 | -1.05% | -96.82% | N/A | N/A | vs NIVF |
| 4PRFX | $72,527 | $0.90 | +1.84% | -87.06% | -74.50% | N/A | vs NIVF |
| 5PBM | $96,046 | $5.05 | -0.59% | -73.54% | N/A | N/A | vs NIVF |
| 6SLXN | $109,400 | $0.26 | -1.84% | -99.31% | N/A | N/A | vs NIVF |
forward FY estimate
N/A
Consensus Rating
Based on 1 analyst
Average Price Target
$127.08
+127875.9% upside
Low
$127.08
Current
$0.10
High
$127.08
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1668.60 | $1668.60 | $1668.60 | 1 |
| Quarter ending Dec 2026 | $1668.60 | $1668.60 | $1668.60 | 1 |
| Quarter ending Mar 2027 | $18.18 | $18.18 | $18.18 | 1 |
| Quarter ending Jun 2027 | $24.48 | $24.48 | $24.48 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $42.66 | $42.66 | $42.66 | 1 |
| FY 2027 | $84.06 | $84.06 | $84.06 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $2.87M | $2.87M | $2.87M | 1 |
| Quarter ending Dec 2026 | $2.87M | $2.87M | $2.87M | 1 |
| Quarter ending Mar 2027 | $20.10M | $20.10M | $20.10M | 1 |
| Quarter ending Jun 2027 | $45.10M | $45.10M | $45.10M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $65.10M | $65.10M | $65.10M | 1 |
| FY 2027 | $180.40M | $180.40M | $180.40M | 1 |
